Biomarker discovery of nasopharyngeal carcinoma by proteomics

Expert Review of Proteomics

Volumn 11, Issue 2, 2014, Pages 215-225

  Xiao, Liang ^a   Xiao, Ta ^a   Wang, Zhi Ming ^a   Cho, William C S ^b   Xiao, Zhi Qiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

biomarker; diagnosis; metastasis; nasopharyngeal carcinoma; prognosis; proteomics; recurrence; therapeutic response

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AMYLOID PROTEIN; ANNEXIN; ARACHIDONATE 12 LIPOXYGENASE; BETA TUBULIN; BIOLOGICAL MARKER; CALGRANULIN B; CATHEPSIN B; CATHEPSIN D; CYTOCHROME P450; CYTOKERATIN 18; CYTOKERATIN 19; FIBRONECTIN; GALECTIN 1; GELATINASE A; HEAT SHOCK PROTEIN 70; HISTONE DEMETHYLASE; KALLIKREIN; LIPOCORTIN 1; MANGANESE SUPEROXIDE DISMUTASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREALBUMIN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; SQUAMOUS CELL CARCINOMA ANTIGEN; STATHMIN; STEFIN A; TRANSCRIPTION FACTOR RUNX2; TRANSFERRIN; UNINDEXED DRUG; PROTEOME; TUMOR MARKER;

CANCER PROGNOSIS; CANCER RECURRENCE; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; HUMAN; METASTASIS; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEOMICS; REVIEW; TREATMENT RESPONSE; METABOLISM; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; PROGNOSIS;

HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896966351     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.897613     Document Type: Review

References (77)

1. Feng XP, Yi H, Li MY, et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 2010;70(9):3450-62
2. Su F, Zhu X, Liang Z, et al. Analysis of serum proteome profiles in nasopharyngeal carcinoma with different radiosensitivity. Clin Transl Oncol 2013. [Epub ahead of print]
3. Cho WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007;6:1
4. Minden JS, Dowd SR, Meyer HE, Stuhler K. Difference gel electrophoresis. Electrophoresis 2009;30(Suppl 1):S156-61
5. Penque D. Two-dimensional gel electrophoresis and mass spectrometry for biomarker discovery. Proteomics Clin Appl 2009;3(2):155-72
6. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng 2009;11: 49-79
7. Wilm M. Quantitative proteomics in biological research. Proteomics 2009;9(20): 4590-605
8. Bantscheff M, Lemeer S, Savitski MM, Kuster B. Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Anal Bioanal Chem 2012;404(4):939-65
9. Pan S, Aebersold R, Chen R, et al. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 2009;8(2):787-97
10. Ai P, Wang T, Zhang H, et al. Determination of antibodies directed at EBV proteins expressed in both latent and lytic cycles in nasopharyngeal carcinoma. Oral Oncol 2013;49(4):326-31
11. Cao SM, Liu Z, Jia WH, et al. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One 2011;6(4):e19100
12. Han BL, Xu XY, Zhang CZ, et al. Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev 2012;13(6):2577-81
13. Ferrari D, Codeca C, Bertuzzi C, et al. Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population. BMC Cancer 2012;12:208
14. Gourzones C, Jimenez AS, Busson P. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 2012;118(18):4634; author reply 4634-4635
15. Zeng X, Xiang J, Wu M, et al. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One 2012;7(10):e46367
16. Wong TS, Kwong DL, Sham JS, et al. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res 2004;10(7):2401-6
17. Li F, Guan Y, Chen Z. Proteomics in nasopharyngeal carcinoma. Cell Mol Life Sci 2008;65(7-8):1007-12
18. Ho DW, Yang ZF, Wong BY, et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma. Cancer 2006;107(1):99-107
19. Wei YS, Zheng YH, Liang WB, et al. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer 2008;112(3): 544-51
20. Tao YL, Li Y, Gao J, et al. Identifying FGA peptides as nasopharyngeal carcinoma-associated biomarkers by magnetic beads. J Cell Biochem 2012; 113(7):2268-78
21. Huang YJ, Xuan C, Zhang BB, et al. SELDI-TOF MS profiling of serum for detection of nasopharyngeal carcinoma. J Exp Clin Cancer Res 2009;28:85
22. Chang JT, Chen LC, Wei SY, et al. Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry-plasma peptidomes from nasopharyngeal cancer patients for example. Clin Biochem 2006;39(12):1144-51
23. Chang YH, Wu CC, Chang KP, et al. Cell secretome analysis using hollow fiber culture system leads to the discovery of CLIC1 protein as a novel plasma marker for nasopharyngeal carcinoma. J Proteome Res 2009;8(12):5465-74
24. Wang B, Zaidi N, He LZ, et al. Targeting of the non-mutated tumor antigen HER2/ neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 2012;14:R39
25. Madsen CB, Petersen C, Lavrsen K, et al. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PLoS One 2012;7:e50139
26. Xiao ZQ, Chen Y, Yi B, et al. Identification of nasopharyngeal carcinoma antigens that induce humoral immune response by proteomic analysis. Proteomics Clin Appl 2007;1(7):688-98
27. Meckes DG Jr, Gunawardena HP, Dekroon RM, et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Nat Acad Sci USA 2013; 110(31):E2925-33
28. Hsu MM, Tu SM. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983;52(2):362-8
29. Ferrari D, Codeca C, Bertuzzi C, et al. Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population. BMC Cancer 2012;12:208
30. Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999;59(21):5452-5
31. Chang KP, Wu CC, Chen HC, et al. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics 2010;10(14):2644-60
32. Liao Q, Zhao L, Chen X, et al. Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma. Clin Exp Metastasis 2008;25(4): 465-76
33. Pan C, Tao Y, Zhao M, et al. Comparative serum proteomic analysis involving liver organ-specific metastasis-associated proteins of nasopharyngeal carcinoma. Exp Ther Med 2012;3(6):1055-61
34. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004; 10(1 Pt 1):43-52
35. Cheng AL, Huang WG, Chen ZC, et al. Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis. J Proteome Res 2008;7(6): 2415-26
36. Cheng AL, Huang WG, Chen ZC, et al. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res 2008;14(2):435-45
37. Chen Y, Ouyang GL, Yi H, et al. Identification of RKIP as an invasion suppressor protein in nasopharyngeal carcinoma by proteomic analysis. J Proteome Res 2008;7(12):5254-62
38. Wu Z, Weng D, Li G. Quantitative proteome analysis of overexpressed Cripto-1 tumor cell reveals 14-3-3gamma as a novel biomarker in nasopharyngeal carcinoma. J Proteomics 2013;83:26-36
39. Li J, Mo HY, Xiong G, et al. Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem 2012;287(42):35484-95
40. Li M, Li C, Li D, et al. Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma. Clin Exp Metastasis 2012;29(8):865-77
41. Makitie AA, Macmillan C, Ho J, et al. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003;9(6): 2177-84
42. Jin Y, Cai XY, Cai YC, et al. To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area. Eur J Cancer 2012;48(6):882-8
43. Xia WX, Ye YF, Lu X, et al. The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy. PLoS One 2013;8(10): e76958
44. Jin Y, Cai XY, Cai YC, et al. To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area. Eur J Cancer 2012;48(6):882-8
45. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006;24(34): 5414-18
46. Li XM, Huang WG, Yi H, et al. Proteomic analysis to identify cytokeratin 18 as a novel biomarker of nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2009;135(12): 1763-75
47. Li X, Hu R, Qu J, et al. Identification of nm23-H1 as a metastatic suppressor and prognostic factor in nasopharyngeal carcinoma by proteomic analysis. Zhong Nan Da Xue Xue Bao Yi xue ban 2012; 37(1):17-26
48. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350(24):2461-70
49. Zhang B, Qu JQ, Xiao L, et al. Identification of heat shock protein 27 as a radioresistance-related protein in nasopharyngeal carcinoma cells. J Cancer Res Clin Oncol 2012;138(12):2117-25
50. Wu P, Zhang H, Qi L, et al. Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy. Oncol Rep 2012;27(4):987-94
51. Cho WC, Yip TT, Ngan RK, et al. ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin Chem 2007;53(2):241-50
52. Tang S, Huang W, Zhong M, et al. Identification Keratin 1 as a cDDP-resistant protein in nasopharyngeal carcinoma cell lines. J Proteomics 2012;75(8):2352-60
53. Chow BH, Chua DT, Sham JS, et al. Increased expression of annexin I is associated with drug-resistance in nasopharyngeal carcinoma and other solid tumors. Proteomics Clin Appl 2009;3(6): 654-62
54. Ruan L, Li XH, Wan XX, et al. Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics. Proteome Sci 2011;9:35
55. Huang XW, Zhou W, Chen J, et al. A pilot investigation on serum protein fingerprinting of nasopharyngeal carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2011;46(6):509-12
56. Cao SM, Yu JK, Chen QY, et al. Detection of nasopharyngeal carcinoma using surface-enhanced laser desorption and ionization mass spectrometry profiles of the serum proteome. Chin J Cancer 2010; 29(8):721-8
57. Seriramalu R, Pang WW, Jayapalan JJ, et al. Application of champedak mannosebinding lectin in the glycoproteomic profiling of serum samples unmasks reduced expression of alpha-2 macroglobulin and complement factor B in patients with nasopharyngeal carcinoma. Electrophoresis 2010;31(14):2388-95
58. Tao YL, Liu ZG, Xia YF, Yi W. Establishment of a specific serum proteomic profile model of nasopharyngeal carcinoma by MALDI-TOF MS. Zhonghua Zhong Liu Za Zhi 2011;33(3):188-91
59. Liao QL, Chen XD, Zhao L, Ding YQ. Comparative proteomics of the serum in patients with nasopharyngeal carcinoma: a study with two-dimensional electrophoresis and MALDI-TOF-MS. Nan Fang Yi Ke Da Xue Xue Bao 2008;28(2): 154-8
60. Peng PH, Wu CC, Liu SC, et al. Quantitative plasma proteome analysis reveals aberrant level of blood coagulation-related proteins in nasopharyngeal carcinoma. J Proteomics 2011;74(5):744-57
61. Yi H, Cheng AL, Huang WG, et al. Screening for differentially expressed proteins in nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008;33(5):375-83
62. Tang CE, Tan T, Li C, et al. Identification of Galectin-1 as a novel biomarker in nasopharyngeal carcinoma by proteomic analysis. Oncol Rep 2010;24(2):495-500
63. Chen Y, Tang CE, Ouyang GL, et al. Identification of RKIP as a differentially tyrosine-phosphorylated protein in nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissues by phosphoproteomic approach. Med Oncol 2009;26(4):463-70
64. Xiao Z, Li G, Chen Y, et al. Quantitative proteomic analysis of formalin-fixed and paraffin-embedded nasopharyngeal carcinoma using iTRAQ labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. J Histochem Cytochem 2010;58(6):517-27
65. Li MX, Xiao ZQ, Chen YH, et al. Proteomic analysis of the stroma-related proteins in nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissues. Med Oncol 2010;27(1):134-44
66. Li MX, Xiao ZQ, Liu YF, et al. Quantitative proteomic analysis of differential proteins in the stroma of nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissue. J Cell Biochem 2009;106(4):570-9
67. Ge S, Mao Y, Yi Y, et al. Comparative proteomic analysis of secreted proteins from nasopharyngeal carcinoma-associated stromal fibroblasts and normal fibroblasts. Exp Ther Med 2012;3(5):857-60
68. Feng X, Zhang J, Chen WN, Ching CB. Proteome profiling of Epstein-Barr virus infected nasopharyngeal carcinoma cell line: identification of potential biomarkers by comparative iTRAQ-coupled 2D LC/MSMS analysis. J Proteomics 2011;74(4): 567-76
69. Wu CC, Chien KY, Tsang NM, et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005;5(12):3173-82
70. Chan CM, Wong SC, Lam MY, et al. Proteomic comparison of nasopharyngeal cancer cell lines C666-1 and NP69 identifies down-regulation of annexin II and beta2-tubulin for nasopharyngeal carcinoma. Arch Pathol Lab Med 2008; 132(4):675-83
71. Cao JY, Mansouri S, Frappier L. Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses. J Virol 2012;86(1):382-94
72. Li GP, Wang H, Lai YK, et al. Proteomic profiling between CNE-2 and its strongly metastatic subclone S-18 and functional characterization of HSP27 in metastasis of nasopharyngeal carcinoma. Proteomics 2011;11(14):2911-20
73. Huang WG, Cheng AL, Chen ZC, et al. Targeted proteomic analysis of 14-3-3sigma in nasopharyngeal carcinoma. Int J Biochem Cell Biol 2010;42(1):137-47
74. Liu J, Zhan X, Li M, et al. Mitochondrial proteomics of nasopharyngeal carcinoma metastasis. BMC Med Genomics 2012;5:62
75. Su HF, Zhang XB, Fang M, et al. Protein microarray analysis on changes in protein phosphorylation in recurrent nasopharyngeal carcinoma. Zhonghua Yi Xue Za Zhi 2011; 91(45):3219-322
76. Li L, Huang S, Zhu X, et al. Identification of radioresistance-associated proteins in human nasopharyngeal carcinoma cell lines by proteomic analysis. Cancer Biother Radiopharm 2013;28(5):380-4
77. Zeng GQ, Yi H, Li XH, et al. Identification of the proteins related to p53-mediated radioresponse in nasopharyngeal carcinoma by proteomic analysis. J Proteomics 2011;74(12):2723-33